Literature DB >> 34071039

Structure-Based Discovery of ABCG2 Inhibitors: A Homology Protein-Based Pharmacophore Modeling and Molecular Docking Approach.

Minh-Tri Le1,2, Viet-Nham Hoang1,3, Dac-Nhan Nguyen1, Thi-Hoang-Linh Bui1, Thien-Vy Phan1,4, Phuong Nguyen-Hoai Huynh1, Thanh-Dao Tran1, Khac-Minh Thai1.   

Abstract

ABCG2 is an ABC membrane protein reverse transport pump, which removes toxic substances such as medicines out of cells. As a result, drug bioavailability is an unexpected change and negatively influences the ADMET (absorption, distribution, metabolism, excretion, and toxicity), leading to multi-drug resistance (MDR). Currently, in spite of promising studies, screening for ABCG2 inhibitors showed modest results. The aim of this study was to search for small molecules that could inhibit the ABCG2 pump. We first used the WISS MODEL automatic server to build up ABCG2 homology protein from 655 amino acids. Pharmacophore models, which were con-structed based on strong ABCG2 inhibitors (IC50 < 1 μM), consist of two hydrophobic (Hyd) groups, two hydrogen bonding acceptors (Acc2), and an aromatic or conjugated ring (Aro|PiR). Using molecular docking method, 714 substances from the DrugBank and 837 substances from the TCM with potential to inhibit the ABCG2 were obtained. These chemicals maybe favor synthesized or extracted and bioactivity testing.

Entities:  

Keywords:  ABCG2 inhibitors; homology protein; molecular docking; pharmacophore models; protein reverse transport pump

Year:  2021        PMID: 34071039     DOI: 10.3390/molecules26113115

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  31 in total

1.  4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2).

Authors:  Michael K Krapf; Jennifer Gallus; Michael Wiese
Journal:  J Med Chem       Date:  2017-05-12       Impact factor: 7.446

2.  Computer review of ChemDraw Ultra 12.0.

Authors:  Kimberley R Cousins
Journal:  J Am Chem Soc       Date:  2011-05-11       Impact factor: 15.419

3.  Insight into structural features of phenyltetrazole derivatives as ABCG2 inhibitors for the treatment of multidrug resistance in cancer.

Authors:  B Bhardwaj; A T K Baidya; S A Amin; N Adhikari; T Jha; S Gayen
Journal:  SAR QSAR Environ Res       Date:  2019-06-03       Impact factor: 3.000

4.  Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.

Authors:  Kapil Juvale; Veronika F S Pape; Michael Wiese
Journal:  Bioorg Med Chem       Date:  2011-11-03       Impact factor: 3.641

5.  2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2.

Authors:  Michael K Krapf; Jennifer Gallus; Vigneshwaran Namasivayam; Michael Wiese
Journal:  J Med Chem       Date:  2018-08-20       Impact factor: 7.446

6.  Synthetic Analogs of Curcumin Modulate the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCG2.

Authors:  Megumi Murakami; Shinobu Ohnuma; Michihiro Fukuda; Eduardo E Chufan; Katsuyoshi Kudoh; Keigo Kanehara; Norihiko Sugisawa; Masaharu Ishida; Takeshi Naitoh; Hiroyuki Shibata; Yoshiharu Iwabuchi; Suresh V Ambudkar; Michiaki Unno
Journal:  Drug Metab Dispos       Date:  2017-09-13       Impact factor: 3.922

7.  Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.

Authors:  Shuzhong Zhang; Xinning Yang; Marilyn E Morris
Journal:  Mol Pharmacol       Date:  2004-05       Impact factor: 4.436

8.  Synthesis and quantitative structure-activity relationships of selective BCRP inhibitors.

Authors:  Federico Marighetti; Kerstin Steggemann; Markus Hanl; Michael Wiese
Journal:  ChemMedChem       Date:  2012-11-13       Impact factor: 3.466

9.  TCM Database@Taiwan: the world's largest traditional Chinese medicine database for drug screening in silico.

Authors:  Calvin Yu-Chian Chen
Journal:  PLoS One       Date:  2011-01-06       Impact factor: 3.240

10.  Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro.

Authors:  Yuqi Yang; Ning Ji; Qiu-Xu Teng; Chao-Yun Cai; Jing-Quan Wang; Zhuo-Xun Wu; Zi-Ning Lei; Sabrina Lusvarghi; Suresh V Ambudkar; Zhe-Sheng Chen
Journal:  Front Oncol       Date:  2020-05-12       Impact factor: 6.244

View more
  2 in total

1.  Naturally occurring plant-based anticancerous candidates as prospective ABCG2 inhibitors: an in silico drug discovery study.

Authors:  Mahmoud A A Ibrahim; Alaa H M Abdelrahman; Esraa A A Badr; Nahlah Makki Almansour; Othman R Alzahrani; Muhammad Naeem Ahmed; Mahmoud E S Soliman; Mohamed Ahmed Naeem; Ahmed M Shawky; Peter A Sidhom; Gamal A H Mekhemer; Mohamed A M Atia
Journal:  Mol Divers       Date:  2022-02-28       Impact factor: 2.943

2.  Chalcone Derivatives as Potential Inhibitors of P-Glycoprotein and NorA: An In Silico and In Vitro Study.

Authors:  Minh-Tri Le; Dieu-Thuong Thi Trinh; Trieu-Du Ngo; Viet-Khoa Tran-Nguyen; Dac-Nhan Nguyen; Tung Hoang; Hoang-Minh Nguyen; Tran-Giang-Son Do; Tan Thanh Mai; Thanh-Dao Tran; Khac-Minh Thai
Journal:  Biomed Res Int       Date:  2022-03-26       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.